Figure 1. Mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) changes after intravitreal aflibercept (IVA) treatment at month 12.

(A) Compared with baseline, mean BCVA was significantly improved in the treatment-naive group, but not in the treatment-switched group, while mean CRT was reduced in both the treatment-naive and the treatment-switched groups 12 months after IVA treatment. Two-tailed t-test, **p < 0.01.